<DOC>
	<DOCNO>NCT00159861</DOCNO>
	<brief_summary>Determination effect sildenafil citrate epoprostenol use combination patient pulmonary arterial hypertension</brief_summary>
	<brief_title>The Efficacy Safety Sildenafil Citrate Used Combination With Intravenous Epoprostenol PAH</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patients pulmonary arterial hypertension cause primary PAH , associate connective tissue disease follow surgical repair congenital heart lesion PH PAH</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>